Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12–59 months
Open Access
- 15 September 2025
- journal article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2557676
Abstract
Respiratory syncytial virus (RSV) is a common respiratory pathogen in children. After demonstrating safety and immunogenicity in adults, mRNA-1345 encoding the RSV prefusion (preF) stabilized F glycoprotein was investigated in children. This phase 1, randomized, observer-blind study assessed the safety and immunogenicity of mRNA-1345 (NCT04528719) in RSV-seropositive children (per microneutralization assay) aged 12-59 months and is part of a larger study in multiple populations. Participants received three doses of mRNA-1345 (15 μg or 30 μg) or placebo 56 days apart, with 12-month safety follow-up. Forty-six participants were randomized to receive mRNA-1345 15 μg (n = 15), mRNA-1345 30 μg (n = 16), or placebo (n = 15). mRNA-1345 was well tolerated at both dose levels. The most frequently reported solicited local adverse reaction (AR) was injection site tenderness (15 μg, 27.3%-50.0%; 30 μg, 53.3%-71.4%; placebo, 26.7%-33.3%). Most solicited systemic ARs were grade 1/2, with irritability/crying, loss of appetite, and sleepiness most frequently reported; reactogenicity did not increase with additional doses. Throughout the 12-month follow-up, no serious adverse events (AEs), deaths, AEs of special interest, or AEs leading to study discontinuation were reported. Three medically attended RSV infections were reported among placebo recipients. A single injection increased RSV-A and RSV-B neutralizing antibody titers (geometric mean fold rise [GMFR] over baseline: 15 μg, RSV-A = 18.9, RSV-B = 7.2; 30 μg, RSV-A = 34.9, RSV-B = 14.3) and RSV preF and postF binding antibody concentrations (GMFR: 15 μg, preF = 13.9, postF = 9.3; 30 μg, preF = 26.5, postF = 16.0); binding antibody responses were preF-biased. Subsequent doses did not further increase antibody levels. In conclusion, mRNA-1345 was well tolerated and boosted antibody levels in seropositive children aged 12-59 months.Keywords
Funding Information
- Moderna
This publication has 13 references indexed in Scilit:
- Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older AdultsThe Journal of Infectious Diseases, 2024
- A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization StrategyJournal of the Pediatric Infectious Diseases Society, 2024
- Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older AdultsThe Journal of Infectious Diseases, 2024
- Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical TrialThe Journal of Infectious Diseases, 2024
- Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older AdultsNew England Journal of Medicine, 2023
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023MMWR. Morbidity and Mortality Weekly Report, 2023
- The disease burden of respiratory syncytial virus in InfantsCurrent Opinion in Infectious Diseases, 2023
- A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adultsHuman Vaccines & Immunotherapeutics, 2020
- Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of lifeEpidemiology and Infection, 2016
- Viral Infections of the Lower Respiratory TractCurrent Infectious Disease Reports, 2012